The substantial progression-free survival benefit provided by maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation is achieved with no detrimental effect on patients’ health-related quality of life (HRQOL), Australian researchers say. According to the SOLO1 study – previously reported in the limbic – there was a 70% lower risk ...
PARP inhibitor: PFS benefit without loss of QOL
By Mardi Chapman
18 Apr 2021